Cargando…

Group-specific cellular metabolism in Medulloblastoma

BACKGROUND: Cancer metabolism influences multiple aspects of tumorigenesis and causes diversity across malignancies. Although comprehensive research has extended our knowledge of molecular subgroups in medulloblastoma (MB), discrete analysis of metabolic heterogeneity is currently lacking. This stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Funke, Viktoria L. E., Walter, Carolin, Melcher, Viktoria, Wei, Lanying, Sandmann, Sarah, Hotfilder, Marc, Varghese, Julian, Jäger, Natalie, Kool, Marcel, Jones, David T. W., Pfister, Stefan M., Milde, Till, Mynarek, Martin, Rutkowski, Stefan, Seggewiss, Jochen, Jeising, Daniela, de Faria, Flavia W., Marquardt, Thorsten, Albert, Thomas K., Schüller, Ulrich, Kerl, Kornelius
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242934/ https://www.ncbi.nlm.nih.gov/pubmed/37277823 http://dx.doi.org/10.1186/s12967-023-04211-6

Ejemplares similares

Mitochondrial DNA mutations in Medulloblastoma
por: Funke, Viktoria L. E., et al.
Publicado: (2023)

MEDB-67. Subgroup specific analysis of cellular metabolism in medulloblastoma
por: Funke, Viktoria, et al.
Publicado: (2022)

Smarcb1 Loss Results in a Deregulation of esBAF Binding and Impacts the Expression of Neurodevelopmental Genes
por: Alfert, Amelie, et al.
Publicado: (2022)

The Growing Relevance of Immunoregulation in Pediatric Brain Tumors
por: Melcher, Viktoria, et al.
Publicado: (2021)

A Carboxy-terminal Smarcb1 Point Mutation Induces Hydrocephalus Formation and Affects AP-1 and Neuronal Signalling Pathways in Mice
por: Brugmans, Aliska K., et al.
Publicado: (2023)

MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate
por: Tonn, Svenja, et al.
Publicado: (2022)

ETMR-05. SINGLE-CELL RNA-SEQ OF ETMR REVEALS CELL PROGRAMS OF DEVELOPMENTAL HIERARCHY AND CELLULAR DIVERSITY IN THE TUMOR MICROENVIRONMENT
por: de Faria, Flavia W, et al.
Publicado: (2020)

ETMR-05. Single-cell transcriptomics of ETMR reveals developmental cellular programs and tumor-pericyte communications in the microenvironment
por: de Faria, Flavia W, et al.
Publicado: (2022)

Update on molecular and genetic alterations in adult medulloblastoma
por: Kool, Marcel, et al.
Publicado: (2012)

MEDB-50. Assessment of cellular radiosensitivity and DNA repair in medulloblastoma cell lines and patient-derivded xenograft slice cultures
por: Feyerabend, Simon, et al.
Publicado: (2022)

MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS
por: Mynarek, Martin, et al.
Publicado: (2020)

SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk Medulloblastoma
por: Mynarek, Martin, et al.
Publicado: (2021)

Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts
por: Mynarek, Martin, et al.
Publicado: (2022)

MEDB-37. Chemotherapy response prediction by molecular risk factors in metastatic childhood medulloblastoma
por: Obrecht, Denise, et al.
Publicado: (2022)

MEDB-61. Genetic alterations ofTP53 andOTX2 indicate increased risk of relapse in WNT medulloblastomas
por: Goschzik, Tobias, et al.
Publicado: (2022)

MEDB-36. Clinical and molecular heterogeneity withinMYC andMYCN amplified medulloblastoma
por: Schwalbe, Edward, et al.
Publicado: (2022)

Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study
por: Gaab, Christine, et al.
Publicado: (2022)

Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes
por: Sharma, Tanvi, et al.
Publicado: (2019)

Molecular subgroups of medulloblastoma: the current consensus
por: Taylor, Michael D., et al.
Publicado: (2011)

Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma
por: Begemann, Matthias, et al.
Publicado: (2020)

MEDB-38. Significance of CSF cytology and neurologic deterioration in relapsed medulloblastomas in the German HIT-REZ-97/-2005 Studies and the HIT-REZ-Register
por: Tschirner, Sebastian, et al.
Publicado: (2022)

Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression
por: Korshunov, Andrey, et al.
Publicado: (2022)

ATRT-13. DIFFERENT CELLS OF ORIGIN PAVE THE WAY FOR MOLECULAR HETEROGENEITY IN RHABDOID TUMORS
por: Graf, Monika, et al.
Publicado: (2020)

MEDB-16. Persistent radiological lesions at the end of primary therapy in childhood medulloblastoma: residual lesion or active residual tumor?
por: Schömig, Lena, et al.
Publicado: (2022)

MDB-19. MULTIOMIC PROFILING OF MEDULLOBLASTOMA REVEALS SUBTYPE-SPECIFIC TARGETABLE ALTERATIONS AT THE PROTEOME AND N-GLYCAN LEVEL
por: Godbole, Shweta, et al.
Publicado: (2023)

MEDB-17. Re-irradiation for recurrent medulloblastoma in a matched cohort: Advantageous especially in patients without resection
por: Adolph, Jonas E, et al.
Publicado: (2022)

MEDB-51. Impact of residual tumor on outcomes in children and adolescents with medulloblastoma in the German HIT-cohort
por: Wolgast, Stella, et al.
Publicado: (2022)

Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort
por: Pietsch, Torsten, et al.
Publicado: (2014)

The tumor suppressor CREBBP and the oncogene MYCN cooperate to induce malignant brain tumors in mice
por: Schoof, Melanie, et al.
Publicado: (2023)

Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies
por: Obrecht, Denise, et al.
Publicado: (2022)

QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL
por: Mynarek, Martin, et al.
Publicado: (2020)

ATRT-14. MACROPHAGE-TUMOR CELL INTERACTION PROMOTES ATRT PROGRESSION AND CHEMORESISTANCE
por: Melcher, Viktoria, et al.
Publicado: (2020)

Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
por: Ecker, Jonas, et al.
Publicado: (2015)

Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies
por: Adolph, Jonas E., et al.
Publicado: (2021)

Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas
por: Goschzik, Tobias, et al.
Publicado: (2022)

EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN MYC-AMPLIFIED MEDULLOBLASTOMA
por: Valinciute, Gintvile, et al.
Publicado: (2021)

MODL-03. Establishment of intraventricular Shh inhibition as a therapeutic option for young patients with medulloblastoma
por: Kresbach, Catena, et al.
Publicado: (2022)

MBCL-21. GERMLINE ELONGATOR MUTATIONS IN SONIC HEDGEHOG MEDULLOBLASTOMA
por: Robinson, Giles W, et al.
Publicado: (2020)

Defining a Characteristic Gene Expression Set Responsible for Cancer Stem Cell-Like Features in a Sub-Population of Ewing Sarcoma Cells CADO-ES1
por: Hotfilder, Marc, et al.
Publicado: (2018)

MBRS-48. IDENTIFICATION OF NOVEL THERAPEUTIC APPROACHES FOR MYC-DRIVEN MEDULLOBLASTOMA
por: Taban, Kübra, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_phoh5m01bmgcm6a7bjpsvpjeag